Chiome Bioscience : Supplementary Information for Financial Results FY12/21

Supplementary Information for Financial Results FY12/21

Feb. 14, 2022

To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

Agenda

１．Overview of FY12/21 "Financial results"

２．Overview of FY12/21 "Operation highlights"

Appendix.

Corporate information

Pipeline information

		2
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved.

Overview of

FY12/21 "Financial results"

Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.

		3
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved.

Financial results: Profit and Loss

					(JPY in millions)
	FY2020	FY2021	Increase	Main reasons for increase / decrease
		(decrease)
Net sales	480	712		232
Drug Discovery &	3	103		99	• Upfront payment of the License
Development		Agreement with Shanghai Henlius Biotech,
				Inc. for LIV-2008/2008b
Drug Discovery	477	609		132	• Growth in business with domestic
Support					pharmaceutical companies
COS/SGA	1,764	2,047		282
R&D Expense	1,156	1,312		155	• Cost of the study drug manufacturing in
	CBA-1535 program
Other costs	607	735		127	• Up in material costs due to increased
					business transactions
Operating Loss	(1,283)	(1,334)		(50)
Ordinary Loss	(1,291)	(1,329)		(37)	• Revenue from AMED grants
Net Loss	(1,293)	(1,479)		(186)	• Loss on devaluation of investment
					securities

		4
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved.

Financial results: Balance Sheet

		(JPY in millions)
	As of Dec. 31, 2020	As of Dec. 31, 2021
Current assets	3,248	2,216
（Cash on hand in banks)	2,686	1,790
(Other current assets)	562	425
			①
Non-current assets	246	122
Total assets	3,494	2,339
Current Liabilities	342	392
Non-current liabilities	41	53
Total liabilities	384	446
Total net assets	3,109	1,893	②
Total liabilities and net assets	3,494	2,339

Explanation of balance sheet

① Non-current assets decreased due to impairment of investment securities of investees. ②Retained earnings -1,479 million yen

		5
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved.